BIOX Bioceres Crop Solutions Corp. - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
BIOX Stock | Fundamental Analysis & Investment Insights
NASDAQ
Basic Materials
Agricultural Inputs
Current Price
Live
$1.2
Analyst Target
$2.0
+66.7%
Upside
52W High
$7.17
52W Low
$1.17
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$76.17M
P/E
N/A
ROE
-18.9%
Profit margin
-17.7%
Debt/Equity
0.9
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
92%
Analysis Accuracy
The deterministic health scores paint a dire picture: BIOX has a Piotroski F-Score of just 2/9, indicating severe financial weakness. Despite low valuation multiples like a Price/Book of 0.29 and Price/Sales of 0.24, the company is unprofitable with a -17.72% profit margin and deteriorating fundamentals, including -16.40% YoY revenue growth and a -300% YoY EPS decline. Earnings volatility is extreme, with a history of massive negative surprises averaging -268.89% over the last four quarters, and the stock has lost over 85% of its value in five years. While the Forward P/E of 1.88 may appear attractive, it is unsupported by cash flow, balance sheet clarity, or consistent earnings, and the lack of an Altman Z-Score due to missing data further elevates risk.
Key Strengths
Extremely low valuation multiples (P/B = 0.29, P/S = 0.24) suggest deep discounting relative to book and sales
Gross margin remains relatively healthy at 39.42%, indicating some pricing power or cost control at the production level
Forward P/E of 1.88 implies very low expectations, potentially pricing in significant distress
Insider sentiment score of 40/100 shows no extreme selling pressure, though not bullish
Debt/Equity of 0.90 is within sector average range, not excessively leveraged on paper
Key Risks
Piotroski F-Score of 2/9 signals critical financial distress and high risk of continued underperformance
Profitability collapsing: -17.72% net margin and -18.95% ROE indicate value destruction
Revenue declining YoY by 16.40% with no signs of stabilization
Extreme earnings unpredictability: 1/4 recent quarters beat estimates, with average surprise of -268.89%
Lack of key financial data (Altman Z-Score, cash/debt figures, EV, FCF) suggests opacity or reporting issues, increasing investment risk
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
18
Weak
45
20
15
10
0
AI Verdict
Highly risky with poor fundamentals and unreliable earnings; not suitable for defensive or income investors
Key drivers: Piotroski F-Score of 2/9, Negative profitability across net, ROE, and ROA, Deteriorating revenue and earnings trends, Extreme earnings volatility and miss frequency, Missing Altman Z-Score and cash flow data
Confidence
94%
Value
45/100
Ref P/E, PEG, Graham Number
Positives
- Price/Book of 0.29 is deeply discounted
- Price/Sales of 0.24 is well below sector average
Watchpoints
- P/E is N/A due to losses; Forward P/E of 1.88 is based on unreliable projections
- No Graham Number or Intrinsic Value available due to unprofitability
- Low multiples reflect distress, not opportunity
Future
20/100
Ref Growth rates
Positives
- Forward P/E of 1.88 implies low growth expectations already priced in
Watchpoints
- Revenue Growth (YoY): -16.40%
- Earnings Growth (YoY): -300.0%
- No reliable analyst target consensus due to single analyst coverage
Past
15/100
Ref Historical trends
Positives
- One quarter (2023-05-10) showed a +1215.5% earnings surprise
Watchpoints
- 24 of 25 quarters show earnings misses or losses
- Average surprise over last 4 quarters: -268.89%
- 5Y price return: -85.0%, significantly underperforming
Health
10/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Debt/Equity of 0.90 is below sector average of 0.81 (though data gaps exist)
Watchpoints
- Piotroski F-Score: 2/9 (critical weakness)
- Current Ratio: 0.94 (below 1.0 threshold)
- Quick Ratio: 0.62 (liquidity risk)
- ROA: -0.39%, ROE: -18.95%
- No Altman Z-Score due to missing data — potential red flag
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- Dividend Strength: 0/100
- No dividend yield or payout history
- No capacity to pay dividends given losses
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$1.2
Analyst Target
$2.0
Upside/Downside
+66.7%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for BIOX and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
BIOX
Bioceres Crop Solutions Corp.
Primary
|
-85.0% | -90.1% | -82.5% | -68.0% | -11.8% | -7.0% |
|
ACNT
Ascent Industries Co.
Peer
|
+29.2% | +48.5% | +3.6% | +1.1% | -27.8% | -3.5% |
|
BON
Bon Natural Life Limited
Peer
|
-99.9% | -99.4% | -95.2% | +23.2% | +3.0% | +1.2% |
|
AVD
American Vanguard Corporation
Peer
|
-72.7% | -78.1% | -12.5% | +31.6% | +23.4% | +14.2% |
|
BGLC
BioNexus Gene Lab Corp.
Peer
|
-98.9% | -97.4% | -9.3% | -36.3% | -24.8% | -14.2% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
1.88
PEG Ratio
N/A
P/B Ratio
0.29
P/S Ratio
0.24
EV/Revenue
1.09
EV/EBITDA
29.44
Market Cap
$76.17M
Profitability
Profit margins and return metrics
Profit Margin
-17.72%
Operating Margin
8.92%
Gross Margin
39.42%
ROE
-18.95%
ROA
-0.39%
Growth
Revenue and earnings growth rates
Revenue Growth
-16.4%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.9
Moderate
Current Ratio
0.94
Weak
Quick Ratio
0.62
Poor
Cash/Share
$0.26
Quarterly Earnings History
EPS performance vs analyst estimates
2026-02-11
$N/A
2025-11-12
$-0.12
-50.6% surprise
2025-09-09
$-0.7
-837.8% surprise
2025-05-21
$-0.02
+81.7% surprise
Basic Materials Sector Comparison
Comparing BIOX against 41 companies in the Basic Materials sector
(1 bullish, 21 neutral, 19 bearish)
Return on Equity (ROE)
-18.95%
This Stock
vs
0.39%
Sector Avg
-4901.0%
(Below Avg)
Profit Margin
-17.72%
This Stock
vs
-2.52%
Sector Avg
+602.2%
(Superior)
Debt to Equity
0.9
This Stock
vs
0.61
Sector Avg
+48.0%
(Higher)
Revenue Growth
-16.4%
This Stock
vs
14.81%
Sector Avg
-210.8%
(Slower)
Current Ratio
0.94
This Stock
vs
2.28
Sector Avg
-58.5%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
BIOX
Bioceres Crop Solutions Corp.
|
BEARISH | $76.17M | - | -18.9% | -17.7% | $1.2 | |
|
ACNT
Ascent Industries Co.
|
BEARISH | $119.97M | - | -6.2% | 1.2% | $12.79 | |
|
BON
Bon Natural Life Limited
|
BEARISH | $17.29M | 0.08 | 1.2% | 2.7% | $1.7 | |
|
AVD
American Vanguard Corporation
|
BEARISH | $139.78M | - | -40.8% | -21.1% | $4.91 | |
|
BGLC
BioNexus Gene Lab Corp.
|
BEARISH | $7.38M | - | -28.3% | -24.3% | $3.12 |
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
1 analysts
Canaccord Genuity
2026-01-02
Hold
Hold
Canaccord Genuity
2025-11-14
Hold
Hold
Lake Street
2025-09-10
Buy
Buy
Canaccord Genuity
2025-09-10
Buy
Hold
Past News Coverage
Recent headlines mentioning BIOX from our newsroom.
Newest → oldest
No matching news yet.